PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
2.36%
Cash & equivalents yoy growth 0.75-0.9x TRAW's 3.03%. Bill Ackman might demand clarity on why growth lags the competitor's liquidity build.
No Data
No Data available this quarter, please select a different quarter.
2.36%
Cash + STI yoy 0.75-0.9x TRAW's 3.03%. Bill Ackman would wonder if competitor is building liquidity more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.66%
Other current assets growth < half of TRAW's 121.67%. David Dodd sees a leaner approach to short-term items.
1.99%
0.5-0.75x TRAW's 2.85%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-7.06%
Below half TRAW's -22.22%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRAW and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.24%
Below half of TRAW's -21.05%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
1.71%
0.5-0.75x TRAW's 2.83%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
22.15%
Less than half of TRAW's -6.00%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half of TRAW's 0.44%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
20.63%
Above 1.5x TRAW's 5.18%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.37%
Less than half of TRAW's -2.12%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
3.44%
Similar yoy to TRAW's 3.54%. Walter Schloss sees parallel expansions in total liabilities.
6.90%
Less than half of TRAW's 19.91%. David Dodd sees fewer share issuances vs. competitor.
-3.28%
Below half TRAW's -25.25%. Michael Burry suspects major net losses or high dividends vs. competitor.
100.00%
Less than half of TRAW's -10.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to TRAW's zero value, indicating worse performance.
-0.05%
Below half TRAW's -1854.28%. Michael Burry sees potential underperformance in building shareholder capital.
1.71%
0.5-0.75x TRAW's 2.83%. Martin Whitman sees underexpansion or possible missed opportunities.
0.63%
Higher Total Investments Growth compared to TRAW's zero value, indicating better performance.
-6.71%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
-2.57%
Similar yoy changes to TRAW's -3.03%. Walter Schloss sees parallel net leverage strategies.